439 TGF-beta2 suppression by the antisense oligonucleotide AP 12009 as therapy for high-grade glioma: safety and efficacy results of phase I/II clinical studies
K. Schlingensiepen, P. Hau, A. Brawanski, J. Schlaier, M. Mehdorn, G. Wurm, J. Pichler, M. Kunst, G. Stauder, U. BogdahnVolume:
2
Year:
2004
Language:
english
DOI:
10.1016/s1359-6349(04)80447-6
File:
PDF, 293 KB
english, 2004